Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23588025 | 0.86 | ESR1 (0.46) | OPRM1ESR2ESR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2474626 | 0.82 | ESR1 (0.48) | OPRM1ESR2ESR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL10390699 | 0.82 | ESR1 (0.54) | OPRM1ESR2ESR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3903587 | 0.81 | OPRM1 (0.40) | OPRM1ALDH1A1SMN1; SMN2MEN1NPC1 | |
| SCHEMBL3237390 | 0.81 | OPRM1 (0.40) | OPRM1ALDH1A1SMN1; SMN2MEN1NPC1 | |
| SCHEMBL2131500 | 0.81 | OPRM1 (0.58) | OPRM1ALDH1A1SMN1; SMN2MEN1NPC1 | |
| SCHEMBL13594179 | 0.81 | OPRM1 (0.60) | OPRM1 | |
| SCHEMBL625655 | 0.81 | OPRM1 (0.40) | OPRM1ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL625403 | 0.81 | OPRM1 (0.58) | OPRM1ALDH1A1 | |
| SCHEMBL15647881 | 0.81 | CYP11B2 (0.36) | OPRM1CA12CA2CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651930-B1 | BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2015-10-28 | — | — | EP | disclosed |
| US-9073895-B2 | Biarylamide inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-9073895-B2 | Biarylamide inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-20120322795-A1 | BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| WO-2012082817-A1 | BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | WO | disclosed |
| EP-1747210-B1 | 3- OR 4-MONOSUBSTITUTED PHENOL AND THIOPHENOL DERIVATIVES USEFUL AS H3 LIGANDS | WARNER LAMBERT CO (US) | 2010-06-30 | — | — | EP | disclosed |
| EP-1747210-B1 | 3- OR 4-MONOSUBSTITUTED PHENOL AND THIOPHENOL DERIVATIVES USEFUL AS H3 LIGANDS | WARNER LAMBERT CO (US) | 2010-06-30 | — | — | EP | disclosed |
| US-7456164-B2 | Useful for treatment of H3-related diseases such as neurologic disorders, or inflammatory, respiratory and allergic diseases, disorders and conditions; for example, 4-[4-(1-isopropylpiperidin-4-yloxy)phenyl]tetrahydropyran-4-carbonitrile; well absorbed from gastrointestinal tract, metabolically stable | PFIZER, INC (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456164-B2 | Useful for treatment of H3-related diseases such as neurologic disorders, or inflammatory, respiratory and allergic diseases, disorders and conditions; for example, 4-[4-(1-isopropylpiperidin-4-yloxy)phenyl]tetrahydropyran-4-carbonitrile; well absorbed from gastrointestinal tract, metabolically stable | PFIZER, INC (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456164-B2 | Useful for treatment of H3-related diseases such as neurologic disorders, or inflammatory, respiratory and allergic diseases, disorders and conditions; for example, 4-[4-(1-isopropylpiperidin-4-yloxy)phenyl]tetrahydropyran-4-carbonitrile; well absorbed from gastrointestinal tract, metabolically stable | PFIZER, INC (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1747210-A1 | 3- OR 4-MONOSUBSTITUTED PHENOL AND THIOPHENOL DERIVATIVES USEFUL AS H3 LIGANDS | Warner-Lambert Company LLC (US) | 2007-01-31 | — | — | EP | disclosed |
| US-20050267095-A1 | 3- or 4-monosubstituted phenol and thiophenol derivatives useful as H3 ligands | ZIARCO INC. | 2005-12-01 | — | — | US | disclosed |
| WO-2005108384-A1 | 3- OR 4-MONOSUBSTITUTED PHENOL AND THIOPHENOL DERIVATIVES USEFUL AS H3 LIGANDS | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-17 | — | — | WO | disclosed |
| EP-1593679-A1 | 3- Or 4-monosubstituted phenol derivatives useful as H3 ligands | Warner-Lambert Company LLC (US) | 2005-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322795-A1 | BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTB4R2, LTC4S | OPRM1 4011/4885ESR2 1907/4885ESR1 3028/4885 |
| US-20050267095-A1 | 3- or 4-monosubstituted phenol and thiophenol derivatives useful as H3 ligands | HRH4, HRH3, TLR4 | OPRM1 1739/4885ESR2 423/4885ESR1 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.